Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib
The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.
Gastro Intestinal Stromal Tumor
DRUG: masitinib|DRUG: sunitinib
overall progression free survival, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 weeks, up to 36 weeks
overall survival, From date of randomization until the date of death from any cause, assessed up to 36 weeks, up to 36 weeks
The objective is to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib.